[Magnesium deficiency caused by epirubicin/cisplatin].
In 19 patients receiving a cytostatic therapy with epirubicine and cisplatinum, 31 times in total the renal loss of magnesium was determined using the colorimetric xylidile-blue-method. 16 patients, whose magnesium input postoperatively was equally well known, served as a control. In all these patients a negative magnesium balance could be demonstrated being significantly higher (p less than 0.01) in those receiving cytostatic therapy.
Lechner
W
W
Universitätsklinik für Frauenheilkunde, Innsbruck.
Söldner
E
E
Sachsenmaier
M
M
Philadelphy
H
H
Jarosch
E
E
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005665:Furosemide / Q000008:administration & dosage / Q000009:adverse effects; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D008274:Magnesium / Q000652:urine; D008275:Magnesium Deficiency / Q000139:chemically induced*; D008875:Middle Aged
D015251:Epirubicin; D005665:Furosemide; D008274:Magnesium; D002945:Cisplatin
Magnesiumverarmung unter Epirubicin/Cisplatin.